Kazia Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	-	0.04	2.31	-	-	15.18
Revenue Growth (YoY)	-	-98.19%	-	-	-	-
Gross Profit	-	0.04	2.31	-	-	15.18
Selling, General & Admin	16.44	8.72	13.56	8.58	5.24	7.02
Research & Development	10.53	7.33	17.38	15.56	20.17	14.54
Other Operating Expenses	1.9	15.17	0.17	0	0.03	0
Total Operating Expenses	28.87	31.21	31.12	24.15	25.43	21.56
Operating Income	-28.87	-31.17	-28.81	-24.15	-25.43	-6.38
Interest Income	0.28	0.07	0.01	0.02	0	0.04
Other Non-Operating Income (Expense)	1.12	5.08	0.12	3.39	-	-2.57
Total Non-Operating Income (Expense)	1.4	5.15	0.13	3.41	0	-2.53
Pretax Income	-30.68	-22.45	-27.05	-20.74	-25.38	-8.9
Provision for Income Taxes	-1.61	-1.75	-0.27	-0.27	-0.37	-0.48
Net Income	-29.07	-20.7	-26.78	-20.47	-25.01	-8.42
Net Income to Common	-29.07	-20.7	-26.78	-20.47	-25.01	-8.42
Shares Outstanding (Basic)	0	1	1	0	0	0
Shares Outstanding (Diluted)	0	1	1	0	0	0
Shares Change (YoY)	-78.90%	107.81%	43.08%	39.12%	12.57%	61.08%
EPS (Basic)	-32.23	-18.90	-50.80	-56.15	-94.40	-35.80
EPS (Diluted)	-32.23	-18.90	-50.80	-56.15	-94.40	-35.80
Free Cash Flow	-13.04	-8.78	-6.39	-10.1	-15.7	-6.83
Free Cash Flow Per Share	-68.31	-8.01	-12.12	-27.40	-59.26	-29.03
Gross Margin	-	100.00%	100.00%	-	-	100.00%
Operating Margin	-	-74635.50%	-1248.18%	-	-	-42.02%
Profit Margin	-	-49567.60%	-1160.23%	-	-	-55.46%
FCF Margin	-	-31968.80%	-415.12%	-	-	-60.01%
EBITDA	-19.52	-19.88	-17.98	-14.84	-16.25	-3.84
EBITDA Margin	-	-72397.40%	-1167.20%	-	-	-33.69%
EBIT	-28.87	-31.17	-28.81	-24.15	-25.43	-6.38
EBIT Margin	-	-74635.50%	-1248.18%	-	-	-42.02%
Effective Tax Rate	5.13%	7.78%	1.00%	1.31%	1.45%	5.44%

SEC Filings: 10-K · 10-Q